As GLP-1s target adiposity, those neglected factors may finally come into focus
The molecule incorporates a C20 diacid fatty acid side chain, slightly longer than the C18 side chain used in semaglutide
Research in earlier phases or small trials include evaluation of GLP-1s for indications such as cystic fibrosis-related diabetes, polycystic ovarian syndrome (PCOS), chronic obstructive pulmonary disease (COPD), Prader-Willi syndrome (PWS), asthma, substance or alcohol use disorder, and as add-on to insulin for type 1 diabetes
Either timing can be beneficial, but for optimal results, consider both before and after drinking
Ozempic (semaglutide injection) Summary of Product Characteristics